| Prev Close | 175.62 |
| Day Low/High | 174.61 / 176.85 |
| 52 Wk Low/High | 130.09 / 176.64 |
| Avg Volume | 2.88M |
| Exchange | NASDAQ |
| Shares Outstanding | 748.36M |
| Market Cap | 131.43B |
| EPS | 9.20 |
| P/E Ratio | 15.84 |
| Div & Yield | 4.00 (2.30%) |
Latest News
New Setback for Sanofi's Lantus Increases Need for M&A
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)
First Study to Demonstrate That Lowering LDL Cholesterol With a PCSK9 Inhibitor Impacts Underlying Atherosclerotic Disease on top of Optimized Statin Therapy
Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
FRAME Data Simultaneously Published in New England Journal of Medicine and Presented at ASBMR Showed Treatment With Romosozumab Significantly Reduced New Vertebral and Clinical Fractures Through 12 Months
Gilead: Horse of a Different, uh, Color
The once-mighty biotech has fallen, but entry opportunities will surface.
Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting
The FDA told Spectrum not to seek approval for its bladder cancer drug. Spectrum filed anyway but never told investors about the FDA warning.
Amgen Receives Positive CHMP Opinion For Parsabiv™ (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis
Novel Treatment Administered Intravenously Would put Delivery of Important Therapy in the Hands of the Healthcare Provider
Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine
Significantly Greater Proportion of Patients on Erenumab Experienced a 50 Percent or More Reduction in Number of Migraine Days Compared to Placebo
Amgen (AMGN) Stock Is Wednesday's 'Chart of the Day'
Amgen's (AMGN) last run to highs stalled out, but the stock could still push through the old highs, according to TheStreet's Chris Versace and Bob Lang.
Is Amgen the Cure for the Market Blues?
The shares have some power and legs to get up and through old highs.
AbbVie's Battle Royale
Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?
Big Pharma Spends Millions to Keep Prices High for California Agencies
Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.
Here's When You Should Buy Amgen
Shares of Amgen are under pressure today. Here's how to trade it from here.
Amgen To Highlight 19 Abstracts On Osteoporosis Disease State And Treatment At American Society For Bone And Mineral Research Annual Meeting
Results From Phase 3 FRAME Study of Romosozumab Evaluate Fracture Risk Reduction in Women With Postmenopausal Osteoporosis
Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug
Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.
Amgen Has Many Ways to Win
Investors have been cautious on Amgen, but the company has a strong pipeline of drugs in development.
Will Amgen (AMGN) Stock Be Helped by Servier Drug Partnership Extension?
Amgen (AMGN) and the French pharmaceutical company Servier announced today that they'd extended a partnership on development and commercialization of their chronic heart failure drug.
Amgen And Servier Extend Omecamtiv Mecarbil Collaboration In Chronic Heart Failure
Servier Provides Notice to Exercise Commercialization Option in Europe and Commonwealth of Independent States, Including Russia
Gilead Sinking Stock Price Calls Out for New Rescue Plan
Investors once OK with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress.
Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy
Study Indicates That Prolia Led to Greater Gains in Bone Mineral Density at 12 Months Compared With Risedronate in Patients Receiving Glucocorticoid Therapy
